63 related articles for article (PubMed ID: 18783878)
1. Inhibition of NF-kappaB in fusogenic membrane glycoprotein causing HL-60 cell death: implications for acute myeloid leukemia.
Tan L; Jia H; Liu R; Wu J; Han H; Zuo Y; Yang S; Huang W
Cancer Lett; 2009 Jan; 273(1):114-21. PubMed ID: 18783878
[TBL] [Abstract][Full Text] [Related]
2. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.
Higuchi H; Bronk SF; Bateman A; Harrington K; Vile RG; Gores GJ
Cancer Res; 2000 Nov; 60(22):6396-402. PubMed ID: 11103804
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
4. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
[TBL] [Abstract][Full Text] [Related]
5. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
6. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy.
Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG
Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474
[TBL] [Abstract][Full Text] [Related]
7. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth.
Bateman A; Bullough F; Murphy S; Emiliusen L; Lavillette D; Cosset FL; Cattaneo R; Russell SJ; Vile RG
Cancer Res; 2000 Mar; 60(6):1492-7. PubMed ID: 10749110
[TBL] [Abstract][Full Text] [Related]
8. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
[TBL] [Abstract][Full Text] [Related]
9. A hyperfusogenic gibbon ape leukemia envelope glycoprotein: targeting of a cytotoxic gene by ligand display.
Fielding AK; Chapel-Fernandes S; Chadwick MP; Bullough FJ; Cosset FL; Russell SJ
Hum Gene Ther; 2000 Apr; 11(6):817-26. PubMed ID: 10779159
[TBL] [Abstract][Full Text] [Related]
10. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells.
Bateman AR; Harrington KJ; Kottke T; Ahmed A; Melcher AA; Gough MJ; Linardakis E; Riddle D; Dietz A; Lohse CM; Strome S; Peterson T; Simari R; Vile RG
Cancer Res; 2002 Nov; 62(22):6566-78. PubMed ID: 12438252
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral expression of a fusogenic membrane glycoprotein enhances the efficacy of replicating adenovirus therapy.
Ahmed A; Jevremovic D; Suzuki K; Kottke T; Thompson J; Emery S; Harrington K; Bateman A; Vile R
Gene Ther; 2003 Sep; 10(19):1663-71. PubMed ID: 12923565
[TBL] [Abstract][Full Text] [Related]
12. Expression of heat shock protein 70 and NKG2D ligands in acute myeloid leukemia cell lines.
Hromadnikova I; Volchenkov R; Sedlackova L; Spacek M; Kozak T
J Recept Signal Transduct Res; 2010 Jun; 30(3):161-9. PubMed ID: 20415540
[TBL] [Abstract][Full Text] [Related]
13. Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein.
Kirkham LA; Bateman AR; Melcher AA; Vile RG; Fielding AK
J Gene Med; 2002; 4(6):592-600. PubMed ID: 12439851
[TBL] [Abstract][Full Text] [Related]
14. Heat-directed tumor cell fusion.
Brade AM; Szmitko P; Ngo D; Liu FF; Klamut HJ
Hum Gene Ther; 2003 Mar; 14(5):447-61. PubMed ID: 12691610
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for acute myeloid leukemia using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Tan L; Xu B; Liu R; Liu H; Tan H; Huang W
Cancer Biol Ther; 2010 Mar; 9(5):350-7. PubMed ID: 20061812
[TBL] [Abstract][Full Text] [Related]
16. Decrease in RelA phosphorylation by inhibiting protein kinase A induces cell death in NF-kappaB-expressing and drug-resistant tumor cells.
Manna SK; Gangadharan C
Mol Immunol; 2009 Apr; 46(7):1340-50. PubMed ID: 19128834
[TBL] [Abstract][Full Text] [Related]
17. The NF-kappaB transcription factor pathway as a therapeutic target in cancer: methods for detection of NF-kappaB activity.
Mauro C; Zazzeroni F; Papa S; Bubici C; Franzoso G
Methods Mol Biol; 2009; 512():169-207. PubMed ID: 19347278
[TBL] [Abstract][Full Text] [Related]
18. Syncytia formation affects the yield and cytotoxicity of an adenovirus expressing a fusogenic glycoprotein at a late stage of replication.
Guedan S; Gros A; Cascallo M; Vile R; Mercade E; Alemany R
Gene Ther; 2008 Sep; 15(17):1240-5. PubMed ID: 18509378
[TBL] [Abstract][Full Text] [Related]
19. An optimized extended DNA kappa B site that enhances plasmid DNA nuclear import and gene expression.
Gonçalves C; Ardourel MY; Decoville M; Breuzard G; Midoux P; Hartmann B; Pichon C
J Gene Med; 2009 May; 11(5):401-11. PubMed ID: 19326361
[TBL] [Abstract][Full Text] [Related]
20. Active adenoviral vascular penetration by targeted formation of heterocellular endothelial-epithelial syncytia.
Chen HH; Cawood R; El-Sherbini Y; Purdie L; Bazan-Peregrino M; Seymour LW; Carlisle RC
Mol Ther; 2011 Jan; 19(1):67-75. PubMed ID: 20877345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
